Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 255

1.

Linking pre-existing biorepositories for medical research: the PopGen 2.0 Network.

Lieb W, Jacobs G, Wolf A, Richter G, Gaede KI, Schwarz J, Arnold N, Böhm R, Buyx A, Cascorbi I, Franke A, Glinicke C, Held-Feindt J, Junker R, Kalthoff H, Kramer HH, Leypoldt F, Maass N, Maetzler W, May S, Mehdorn HM, Röcken C, Schafmayer C, Schrappe M, Schreiber S, Sebens S, Stephani U, Synowitz M, Weimer J, Zabel P, Nöthlings U, Röder C, Krawczak M.

J Community Genet. 2019 Mar 29. doi: 10.1007/s12687-019-00417-8. [Epub ahead of print]

PMID:
30927239
2.

The expression of death receptor systems TRAIL-R1/-R2/-R4, CD95 and TNF-R1 and their cognate ligands in pancreatic ductal adenocarcinoma.

Gaertner F, Krüger S, Röder C, Trauzold A, Röcken C, Kalthoff H.

Histol Histopathol. 2019 May;34(5):491-501. doi: 10.14670/HH-18-054. Epub 2018 Oct 24.

PMID:
30375637
3.

Aberrant DNA methylation of ADAMTS16 in colorectal and other epithelial cancers.

Kordowski F, Kolarova J, Schafmayer C, Buch S, Goldmann T, Marwitz S, Kugler C, Scheufele S, Gassling V, Németh CG, Brosch M, Hampe J, Lucius R, Röder C, Kalthoff H, Siebert R, Ammerpohl O, Reiss K.

BMC Cancer. 2018 Aug 6;18(1):796. doi: 10.1186/s12885-018-4701-2.

4.

Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC.

Gundlach JP, Hauser C, Schlegel FM, Böger C, Röder C, Röcken C, Becker T, Egberts JH, Kalthoff H, Trauzold A.

BMC Cancer. 2018 Jul 31;18(1):777. doi: 10.1186/s12885-018-4688-8.

5.

Identifying patients with an unfavorable prognosis in early stages of colorectal carcinoma.

Hendricks A, Eggebrecht GL, Bernsmeier A, Geisen R, Dall K, Trauzold A, Becker T, Kalthoff H, Schafmayer C, Röder C, Hinz S.

Oncotarget. 2018 Jun 8;9(44):27423-27434. doi: 10.18632/oncotarget.25384. eCollection 2018 Jun 8.

6.

The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells.

Legler K, Hauser C, Egberts JH, Willms A, Heneweer C, Boretius S, Röcken C, Glüer CC, Becker T, Kluge M, Hill O, Gieffers C, Fricke H, Kalthoff H, Lemke J, Trauzold A.

Cell Death Dis. 2018 May 1;9(5):445. doi: 10.1038/s41419-018-0478-0.

7.

E2F1 Signalling is Predictive of Chemoresistance and Lymphogenic Metastasis in Penile Cancer: A Pilot Functional Study Reveals New Prognostic Biomarkers.

Fenner F, Goody D, Protzel C, Erbersdobler A, Richter C, Hartz JM, Naumann CM, Kalthoff H, Herchenröder O, Hakenberg OW, Pützer BM.

Eur Urol Focus. 2018 Jul;4(4):599-607. doi: 10.1016/j.euf.2017.02.009. Epub 2017 Mar 1.

PMID:
28753861
8.

Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations.

Böger C, Krüger S, Behrens HM, Bock S, Haag J, Kalthoff H, Röcken C.

Ann Oncol. 2017 May 1;28(5):1005-1014. doi: 10.1093/annonc/mdx047.

9.

Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells In Vivo.

Leanza L, Romio M, Becker KA, Azzolini M, Trentin L, Managò A, Venturini E, Zaccagnino A, Mattarei A, Carraretto L, Urbani A, Kadow S, Biasutto L, Martini V, Severin F, Peruzzo R, Trimarco V, Egberts JH, Hauser C, Visentin A, Semenzato G, Kalthoff H, Zoratti M, Gulbins E, Paradisi C, Szabo I.

Cancer Cell. 2017 Apr 10;31(4):516-531.e10. doi: 10.1016/j.ccell.2017.03.003.

10.

The prognostic relevance of primary tumor location in patients undergoing resection for pancreatic ductal adenocarcinoma.

Ling Q, Xu X, Ye P, Xie H, Gao F, Hu Q, Liu Z, Wei X, Röder C, Trauzold A, Kalthoff H, Zheng S.

Oncotarget. 2017 Feb 28;8(9):15159-15167. doi: 10.18632/oncotarget.14768.

11.

Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.

Mayerle J, Kalthoff H, Reszka R, Kamlage B, Peter E, Schniewind B, González Maldonado S, Pilarsky C, Heidecke CD, Schatz P, Distler M, Scheiber JA, Mahajan UM, Weiss FU, Grützmann R, Lerch MM.

Gut. 2018 Jan;67(1):128-137. doi: 10.1136/gutjnl-2016-312432. Epub 2017 Jan 20. Erratum in: Gut. 2018 May;67(5):994.

12.

Detection of circulating tumor cells with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients - a prospective study.

Hinz S, Hendricks A, Wittig A, Schafmayer C, Tepel J, Kalthoff H, Becker T, Röder C.

BMC Cancer. 2017 Jan 13;17(1):53. doi: 10.1186/s12885-016-3035-1.

13.

Ion channels in control of pancreatic stellate cell migration.

Storck H, Hild B, Schimmelpfennig S, Sargin S, Nielsen N, Zaccagnino A, Budde T, Novak I, Kalthoff H, Schwab A.

Oncotarget. 2017 Jan 3;8(1):769-784. doi: 10.18632/oncotarget.13647.

14.

Increased survival rate by local release of diclofenac in a murine model of recurrent oral carcinoma.

Will OM, Purcz N, Chalaris A, Heneweer C, Boretius S, Purcz L, Nikkola L, Ashammakhi N, Kalthoff H, Glüer CC, Wiltfang J, Açil Y, Tiwari S.

Int J Nanomedicine. 2016 Oct 12;11:5311-5321. eCollection 2016.

15.

Concentration of circulating miRNA-containing particles in serum enhances miRNA detection and reflects CRC tissue-related deregulations.

ElSharawy A, Röder C, Becker T, Habermann JK, Schreiber S, Rosenstiel P, Kalthoff H.

Oncotarget. 2016 Nov 15;7(46):75353-75365. doi: 10.18632/oncotarget.12205.

16.

In silico analysis of the transportome in human pancreatic ductal adenocarcinoma.

Zaccagnino A, Pilarsky C, Tawfik D, Sebens S, Trauzold A, Novak I, Schwab A, Kalthoff H.

Eur Biophys J. 2016 Oct;45(7):749-763. Epub 2016 Sep 21.

PMID:
27652669
17.

Tumor-reducing effect of the clinically used drug clofazimine in a SCID mouse model of pancreatic ductal adenocarcinoma.

Zaccagnino A, Managò A, Leanza L, Gontarewitz A, Linder B, Azzolini M, Biasutto L, Zoratti M, Peruzzo R, Legler K, Trauzold A, Kalthoff H, Szabo I.

Oncotarget. 2017 Jun 13;8(24):38276-38293. doi: 10.18632/oncotarget.11299.

18.

Differences and Similarities in TRAIL- and Tumor Necrosis Factor-Mediated Necroptotic Signaling in Cancer Cells.

Sosna J, Philipp S, Fuchslocher Chico J, Saggau C, Fritsch J, Föll A, Plenge J, Arenz C, Pinkert T, Kalthoff H, Trauzold A, Schmitz I, Schütze S, Adam D.

Mol Cell Biol. 2016 Sep 26;36(20):2626-44. doi: 10.1128/MCB.00941-15. Print 2016 Oct 15.

19.

Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1.

Radke DI, Ungefroren H, Helm O, Voigt S, Alp G, Braun H, Hübner S, Dilchert J, Sebens S, Adam D, Kalthoff H, Trauzold A.

Cell Signal. 2016 Nov;28(11):1652-62. doi: 10.1016/j.cellsig.2016.07.016. Epub 2016 Aug 1.

PMID:
27492861
20.

Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts.

Heits N, Heinze T, Bernsmeier A, Kerber J, Hauser C, Becker T, Kalthoff H, Egberts JH, Braun F.

BMC Cancer. 2016 May 20;16:322. doi: 10.1186/s12885-016-2360-8.

21.

PD-L1 is an independent prognostic predictor in gastric cancer of Western patients.

Böger C, Behrens HM, Mathiak M, Krüger S, Kalthoff H, Röcken C.

Oncotarget. 2016 Apr 26;7(17):24269-83. doi: 10.18632/oncotarget.8169.

22.

Cytokeratin 20 positive circulating tumor cells are a marker for response after neoadjuvant chemoradiation but not for prognosis in patients with rectal cancer.

Hinz S, Röder C, Tepel J, Hendricks A, Schafmayer C, Becker T, Kalthoff H.

BMC Cancer. 2015 Dec 16;15:953. doi: 10.1186/s12885-015-1989-z.

23.

Interleukin-6 trans-signaling increases the expression of carcinoembryonic antigen-related cell adhesion molecules 5 and 6 in colorectal cancer cells.

Holmer R, Wätzig GH, Tiwari S, Rose-John S, Kalthoff H.

BMC Cancer. 2015 Dec 16;15:975. doi: 10.1186/s12885-015-1950-1.

24.

Target Gene Discovery for Novel Therapeutic Agents in Cancer Treatment.

Tiwari S, Ammerpohl O, Kalthoff H.

Methods Mol Biol. 2016;1381:181-200. doi: 10.1007/978-1-4939-3204-7_10.

PMID:
26667461
25.

Molecular Mechanisms by Which a Fucus vesiculosus Extract Mediates Cell Cycle Inhibition and Cell Death in Pancreatic Cancer Cells.

Geisen U, Zenthoefer M, Peipp M, Kerber J, Plenge J, Managò A, Fuhrmann M, Geyer R, Hennig S, Adam D, Piker L, Rimbach G, Kalthoff H.

Mar Drugs. 2015 Jul 20;13(7):4470-91. doi: 10.3390/md13074470.

26.
27.

Homoharringtonine, a clinically approved anti-leukemia drug, sensitizes tumor cells for TRAIL-induced necroptosis.

Philipp S, Sosna J, Plenge J, Kalthoff H, Adam D.

Cell Commun Signal. 2015 Apr 29;13:25. doi: 10.1186/s12964-015-0103-0.

28.

TRAIL-R2 promotes skeletal metastasis in a breast cancer xenograft mouse model.

Fritsche H, Heilmann T, Tower RJ, Hauser C, von Au A, El-Sheikh D, Campbell GM, Alp G, Schewe D, Hübner S, Tiwari S, Kownatzki D, Boretius S, Adam D, Jonat W, Becker T, Glüer CC, Zöller M, Kalthoff H, Schem C, Trauzold A.

Oncotarget. 2015 Apr 20;6(11):9502-16.

29.

Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis.

von Karstedt S, Conti A, Nobis M, Montinaro A, Hartwig T, Lemke J, Legler K, Annewanter F, Campbell AD, Taraborrelli L, Grosse-Wilde A, Coy JF, El-Bahrawy MA, Bergmann F, Koschny R, Werner J, Ganten TM, Schweiger T, Hoetzenecker K, Kenessey I, Hegedüs B, Bergmann M, Hauser C, Egberts JH, Becker T, Röcken C, Kalthoff H, Trauzold A, Anderson KI, Sansom OJ, Walczak H.

Cancer Cell. 2015 Apr 13;27(4):561-73. doi: 10.1016/j.ccell.2015.02.014. Epub 2015 Apr 2.

30.

A novel NHE1-centered signaling cassette drives epidermal growth factor receptor-dependent pancreatic tumor metastasis and is a target for combination therapy.

Cardone RA, Greco MR, Zeeberg K, Zaccagnino A, Saccomano M, Bellizzi A, Bruns P, Menga M, Pilarsky C, Schwab A, Alves F, Kalthoff H, Casavola V, Reshkin SJ.

Neoplasia. 2015 Feb;17(2):155-66. doi: 10.1016/j.neo.2014.12.003.

31.

Circulating APRIL levels are correlated with advanced disease and prognosis in rectal cancer patients.

Lascano V, Hahne M, Papon L, Cameron K, Röeder C, Schafmayer C, Driessen L, van Eenennaam H, Kalthoff H, Medema JP.

Oncogenesis. 2015 Jan 26;4:e136. doi: 10.1038/oncsis.2014.50.

32.

Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer.

Goumas FA, Holmer R, Egberts JH, Gontarewicz A, Heneweer C, Geisen U, Hauser C, Mende MM, Legler K, Röcken C, Becker T, Waetzig GH, Rose-John S, Kalthoff H.

Int J Cancer. 2015 Sep 1;137(5):1035-46. doi: 10.1002/ijc.29445. Epub 2015 Jan 29.

33.

Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity.

Madhavan B, Yue S, Galli U, Rana S, Gross W, Müller M, Giese NA, Kalthoff H, Becker T, Büchler MW, Zöller M.

Int J Cancer. 2015 Jun 1;136(11):2616-27. doi: 10.1002/ijc.29324. Epub 2014 Nov 25.

34.

Integrins αvβ3 and αvβ5 as prognostic, diagnostic, and therapeutic targets in gastric cancer.

Böger C, Warneke VS, Behrens HM, Kalthoff H, Goodman SL, Becker T, Röcken C.

Gastric Cancer. 2015 Oct;18(4):784-95. doi: 10.1007/s10120-014-0435-2. Epub 2014 Oct 15.

35.

Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2.

Bertsch U, Röder C, Kalthoff H, Trauzold A.

Cell Death Dis. 2014 Aug 28;5:e1390. doi: 10.1038/cddis.2014.351. Review.

36.

Interleukin-6: a villain in the drama of pancreatic cancer development and progression.

Holmer R, Goumas FA, Waetzig GH, Rose-John S, Kalthoff H.

Hepatobiliary Pancreat Dis Int. 2014 Aug;13(4):371-80. Review.

PMID:
25100121
37.

Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma.

Helm O, Mennrich R, Petrick D, Goebel L, Freitag-Wolf S, Röder C, Kalthoff H, Röcken C, Sipos B, Kabelitz D, Schäfer H, Oberg HH, Wesch D, Sebens S.

PLoS One. 2014 May 5;9(5):e94357. doi: 10.1371/journal.pone.0094357. eCollection 2014.

38.

TRAIL-induced programmed necrosis as a novel approach to eliminate tumor cells.

Voigt S, Philipp S, Davarnia P, Winoto-Morbach S, Röder C, Arenz C, Trauzold A, Kabelitz D, Schütze S, Kalthoff H, Adam D.

BMC Cancer. 2014 Feb 7;14:74. doi: 10.1186/1471-2407-14-74.

39.

Integrins and their ligands are expressed in non-small cell lung cancer but not correlated with parameters of disease progression.

Böger C, Kalthoff H, Goodman SL, Behrens HM, Röcken C.

Virchows Arch. 2014 Jan;464(1):69-78. doi: 10.1007/s00428-013-1506-1. Epub 2013 Nov 26.

PMID:
24276405
40.

Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells.

Haselmann V, Kurz A, Bertsch U, Hübner S, Olempska-Müller M, Fritsch J, Häsler R, Pickl A, Fritsche H, Annewanter F, Engler C, Fleig B, Bernt A, Röder C, Schmidt H, Gelhaus C, Hauser C, Egberts JH, Heneweer C, Rohde AM, Böger C, Knippschild U, Röcken C, Adam D, Walczak H, Schütze S, Janssen O, Wulczyn FG, Wajant H, Kalthoff H, Trauzold A.

Gastroenterology. 2014 Jan;146(1):278-90. doi: 10.1053/j.gastro.2013.10.009. Epub 2013 Oct 9.

PMID:
24120475
41.

The diversity between pancreatic head and body/tail cancers: clinical parameters and in vitro models.

Ling Q, Xu X, Zheng SS, Kalthoff H.

Hepatobiliary Pancreat Dis Int. 2013 Oct;12(5):480-7. Review. Erratum in: Hepatobiliary Pancreat Dis Int. 2017 Jun 15;16(3):302.

PMID:
24103277
42.

Dipeptidase 1 (DPEP1) is a marker for the transition from low-grade to high-grade intraepithelial neoplasia and an adverse prognostic factor in colorectal cancer.

Eisenach PA, Soeth E, Röder C, Klöppel G, Tepel J, Kalthoff H, Sipos B.

Br J Cancer. 2013 Aug 6;109(3):694-703. doi: 10.1038/bjc.2013.363. Epub 2013 Jul 9.

43.

Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma.

Lehnen NC, von Mässenhausen A, Kalthoff H, Zhou H, Glowka T, Schütte U, Höller T, Riesner K, Boehm D, Merkelbach-Bruse S, Kirfel J, Perner S, Gütgemann I.

Histopathology. 2013 Aug;63(2):157-66. doi: 10.1111/his.12115. Epub 2013 Jun 28. Erratum in: Histopathology. 2013 Dec;63(6):886.

PMID:
23808822
44.

Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma.

Unruh D, Turner K, Srinivasan R, Kocatürk B, Qi X, Chu Z, Aronow BJ, Plas DR, Gallo CA, Kalthoff H, Kirchhofer D, Ruf W, Ahmad SA, Lucas FV, Versteeg HH, Bogdanov VY.

Int J Cancer. 2014 Jan 1;134(1):9-20. doi: 10.1002/ijc.28327. Epub 2013 Jul 27.

45.

Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.

Chitadze G, Lettau M, Bhat J, Wesch D, Steinle A, Fürst D, Mytilineos J, Kalthoff H, Janssen O, Oberg HH, Kabelitz D.

Int J Cancer. 2013 Oct 1;133(7):1557-66. doi: 10.1002/ijc.28174. Epub 2013 Apr 18.

46.

Validation and comparison of anti-αvβ3 and anti-αvβ5 rabbit monoclonal versus murine monoclonal antibodies in four different tumor entities.

Böger C, Kalthoff H, Goodman SL, Röcken C.

Appl Immunohistochem Mol Morphol. 2013 Dec;21(6):553-60. doi: 10.1097/PAI.0b013e318284a03a.

PMID:
23455183
47.

TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xL in pancreatic ductal adenocarcinoma cells.

Zhou DH, Yang LN, Roder C, Kalthoff H, Trauzold A.

Hepatobiliary Pancreat Dis Int. 2013 Feb;12(1):94-8.

PMID:
23392805
48.

Preclinical evaluation of sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastases.

Schem C, Bauerschlag D, Bender S, Lorenzen AC, Loermann D, Hamann S, Rösel F, Kalthoff H, Glüer CC, Jonat W, Tiwari S.

BMC Cancer. 2013 Jan 24;13:32. doi: 10.1186/1471-2407-13-32.

49.

Impact of molecular imaging in preclinical cancer research.

Heneweer C, Kalthoff H.

BMC Proc. 2013 Apr 4;7 Suppl 2:K4. doi: 10.1186/1753-6561-7-S2-K4. eCollection 2013. No abstract available.

50.

Association study identifying polymorphisms in CD47 and other extracellular matrix pathway genes as putative prognostic markers for colorectal cancer.

Lascorz J, Bevier M, V Schönfels W, Kalthoff H, Aselmann H, Beckmann J, Egberts J, Buch S, Becker T, Schreiber S, Hampe J, Hemminki K, Schafmayer C, Försti A.

Int J Colorectal Dis. 2013 Feb;28(2):173-81. doi: 10.1007/s00384-012-1541-4. Epub 2012 Jul 28.

PMID:
23011546

Supplemental Content

Loading ...
Support Center